In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Amgen Find a New Engine?

Executive Summary

Amgen's string of misfortunes has highlighted the group's need to find an alternative growth engine--one which will, necessarily, look very different from the current anemia franchise. The biotech is leaning too heavily on osteoporosis and cancer candidate denosumab.
Advertisement

Related Content

Actelion Follows Innovation into GP Markets
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2008
Best of the Blog: IN VIVO, February 2008
Genzyme: Why Diversification is Starting to Look Smart
Big Pharma's Year of Big Layoffs
Novo Nordisk: Riding High on Diabetes
Amgen's Biotech Shopping Spree
CEO Interview: AstraZeneca's David Brennan
Why EPO Matters
Not-For-Profit Makes Business Sense, Too

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002938

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel